NexgenRx (TSXV:NXG) Current Deferred Revenue: C$0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:NXG NexgenRx Inc TSXV:NXG
50 GF Score
Price C$0.63
GF Value C$0.33
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is NexgenRx Current Deferred Revenue?

NexgenRx TSXV:NXG +1.61% 50 Current Deferred Revenue is C$0.00 Mil as of Jun. 2026. GuruFocus rates TSXV:NXG with a GF Score™ of 50/100 and a GF Value™ of C$0.33 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

NexgenRx's current deferred revenue for the quarter that ended in Jun. 2026 was C$0.00 Mil.

NexgenRx Current Deferred Revenue Related Terms

NexgenRx Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for NexgenRx's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NexgenRx Current Deferred Revenue Chart

NexgenRx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NexgenRx Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSXV:NXG
50GF Score
NexgenRx Inc TSXV:NXG
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of C$0.00 Mil mean?
NexgenRx (TSXV:NXG) has a Current Deferred Revenue of C$0.00 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on NexgenRx and its competitors.
Is NexgenRx's Current Deferred Revenue too high?
NexgenRx's current Current Deferred Revenue is C$0.00 Mil. Overall, NexgenRx has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NexgenRx's Current Deferred Revenue compare to VEEV and BTSG?
NexgenRx's Current Deferred Revenue of C$0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Healthcare Providers & Services company?
A good Current Deferred Revenue depends on the Healthcare Providers & Services industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on NexgenRx and its competitors. NexgenRx's current Current Deferred Revenue is C$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexgenRx stock overvalued right now?
Based on GuruFocus' analysis, NexgenRx (TSXV:NXG) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.33, compared to a current price of C$0.63 — trading 90.9% above its estimated fair value. The current Current Deferred Revenue is C$0.00 Mil. NexgenRx's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For NexgenRx (TSXV:NXG), the current Current Deferred Revenue is C$0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NexgenRx (TSXV:NXG) Overvalued in 2026?

Based on GuruFocus' analysis, NexgenRx stock appears to be overvalued. The current stock price of C$0.63 is trading 90.9% above its estimated GF Value™ of C$0.33. GuruFocus considers NexgenRx to be Significantly Overvalued.

Key valuation signals for TSXV:NXG:

  • Current Deferred Revenue: C$0.00 Mil
  • GF Value™: C$0.33 vs. price of C$0.63 (90.9% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the TSXV:NXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NexgenRx Business Description

Other Exchanges NEGXF:USA
Address 191 The West Mall, Suite 905, Toronto, ON, CAN, M9C 5L6
NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and also provides ancillary services. The various solutions offered by the company include: NexSys, a fully integrated rules-based adjudication platform for real-time processing of drug, dental, and extended health benefit claims; NexAdmin, which enables sponsors to take complete control of benefit plan administration; and NexPSPAssist, a service that helps Patient Support Programs (PSP) to optimize their deliverables to their manufacturer clients. The company has only one operating segment - benefits administration services.
50GF Score

Get the complete analysis for TSXV:NXG

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.63
Price
C$0.33
GF Value